LataMed AI Corp. (OTC: LMED), a digital health and artificial intelligence technology company focused on telehealth infrastructure and healthcare analytics for emerging markets, announced today that it expects to formally submit a corporate action request to FINRA seeking approval of a proposed five-for-one (5-for-1) forward stock split. The proposal also includes proportional increases in the Company’s authorized common stock and authorized preferred stock.
The proposed corporate action would apply proportionally to all issued and outstanding shares of common stock and outstanding preferred stock designations, including the Series C Voting Preferred Stock. According to the Company, the forward stock split is intended to support broader long-term operational scalability, strategic flexibility, capitalization planning, and future growth initiatives as LataMed AI continues advancing telehealth infrastructure deployment, healthcare analytics integration, regulatory progression, and commercialization initiatives throughout Latin America and other targeted emerging markets.
The Company emphasized that the proposed action does not involve any debt restructuring, recapitalization, or reduction in shareholder ownership percentages. No fractional shares are expected to be issued; any fractional interests would be rounded up to the nearest whole share pursuant to approved Board resolutions.
Management stated that the forward stock split is part of a broader effort to align the Company’s capital structure with its ongoing transition into digital healthcare infrastructure and AI-driven telehealth operations. Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., commented: “As we continue advancing our operational and commercialization initiatives throughout Latin America, we believe this proposed forward stock split and proportional capital structure expansion may support broader long-term strategic flexibility, operational scalability, and future growth initiatives as we continue building our healthcare technology platform.”
The Company recently announced the commencement of initial operational activities associated with its telehealth platform infrastructure in Venezuela following receipt of regulatory authorization through the Ministerio del Poder Popular para la Salud and Servicio Autonomo de Contraloria Sanitaria (SACS).
The proposed forward stock split remains subject to FINRA review and approval, completion of applicable regulatory processing, and final corporate implementation procedures. No assurance can be provided regarding the timing or ultimate effectiveness of the proposed corporate action.
For more information, visit https://latamed.ai or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
